The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
Open accessAbstract
Background Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.Methods 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients.Findings The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0.001 for evaluable patients, 35 vs 22%, p<0.005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6.7 vs 4.4 months, p<0.001), and overall survival was higher (median 17.4 vs 14.1 months, p=0.031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable.Interpretation Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar trends were observed for the addition of irinotecan to 5-FU/LV that resulted in an improved objective response rate (49 vs. 31%) and longer time to progression (6.7 vs. 4.4 months), but, in this case, overall survival benefit was significantly increased (17.4 vs. 14.1 months) [140].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [140]
In the citing paper
“So far, chemotherapy has improved overall survival from approximately 6 months in untreated historical cohorts18 to 16–20 months for the doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and oxaliplatin (FOLFOX)19 and doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and irinotecan (FOLFIRI)20 combination therapy within clinical trials.”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [20]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Self-citation(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Self-citationAutosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
Claus, E. B., Risch, N., & Thompson, W. D. (1994) · Cancer · doi:10.1002/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5 · Cited by 942
Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., & Pommier, Y. G. (1989) · PubMed · Cited by 449
Topoisomerase-targeting antitumor drugs
D'Arpa, P., & Liu, L. F. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90041-3 · Cited by 434
Schoenfeld, D. A., & Richter, J. R. (1982) · Biometrics · doi:10.2307/2530299 · Cited by 354
Research works printed but not linked: 6
- Fages, 1997, Tumour response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: analysis of data in 455 fluorouracil-resistant patients treated with irinotecan, Proc ASCO, 16
- Izzo, 1992, Low dose fluorouracil continuous infusion (FuCI) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired intrinsic resistance to fluorouracil or fluorouracil folinic acid (FuFo), Proc AACR, 33, 217
- D'Arpa, 1989, Topoisomerase-targetting antitumour drugs, Biochim Biophys Acta, 989, 163
- De Gramont, 1998, Homerin. A randomized trial of leucovorin and 5-FU with or without oxaliplatin in advanced colorectal cancer, Proc ASCO, 17, 985
- Giachetti, 1997, Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA) with or without oxaliplatin (OXA) in previously untreated patients with metastatic colorectal cancer, Proc ASCO, 16, 229
- Saltz, 1999, Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (PTS with previously untreated matastatic colorectal cancer (CRC), Proc ASCO, 18, 233
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Metadata
- Authors
- Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., & Rougier, P.
- Affiliations
- Royal Marsden Hospital (GB)
- Duran i Reynals Hospital (ES)
- Maidstone Hospital (GB)
- Royal South Hants Hospital (GB)
- Nottingham City Hospital (GB)
- Hôpital Ambroise-Paré (FR)
- Corresponding author
- Douillard, JY
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-03
- Volume
- 355
- Issue
- 9209
- Pages
- 1041-1047
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2128447158
- Cited by
- 3,256
- References
- 19
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 48 · 2023: 71 · 2022: 94 · 2021: 70 · 2020: 65 · 2019: 81 · 2018: 82 · 2017: 96 · 2016: 108 · 2015: 117 · 2014: 121 · 2013: 119 · 2012: 126
- FWCI
- 69.62
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- irinotecan, 5-fluorouracil, leucovorin, metastatic colorectal cancer, first-line chemotherapy, combination chemotherapy, response rate, time to progression, overall survival, chemotherapy toxicity, quality of life
- MeSH terms
- Irinotecan, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Staging, Quality of Life, Colorectal Neoplasms, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(00)02034-1
- The paper
- Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., & Rougier, P. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(00)02034-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.